AVYXA HOLDINGS
SpecialtyAVYXA HOLDINGS is a specialty pharmaceutical company focused on Oncology, Gastroenterology. Key products include FRINDOVYX.
AVYXA HOLDINGS's Key Drugs
AVYXA HOLDINGS's core commercial portfolio centers on FRINDOVYX, VYKOURA, DOCIVYX, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
Malignant Lymphoma
Methotrexate Toxicity
Breast Cancer
Ovarian Cancer
Actinic Keratosis
AVYXA HOLDINGS's Recent FDA Approvals
AVYXA HOLDINGS secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AVYXA HOLDINGS's Therapeutic Areas
AVYXA HOLDINGS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 8 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AVYXA HOLDINGS's Top Competitors
AVYXA HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AVYXA HOLDINGS Pipeline Snapshot
Active clinical trials for AVYXA HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FRINDOVYX leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling